Pure Global
NCT05172037

Novaferon in Non-hospitalized Adult Patients With Mild COVID-19

An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients With Mild COVID-19
Genova Inc.·Phase 3·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Covid19
Drug/Device/Intervention
Novaferon
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Genova Inc.
Location
Tokyo, Japan
Timeline & enrollment
Phase
Phase 3
Start date
Oct 28, 2021
End date
Jun 01, 2022
Enrollment
222 participants
Primary outcome

Rate of severe conditions with Score 3 or more serious on a seven-point ordinal scale from the start date of investigational drug administration (Day 1) to Day 28.

Summary

An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to
 Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult
 Patients with Mild COVID-19

ICD-10 classifications
COVID-19, virus identifiedCOVID-19, virus not identifiedCoronavirus infection, unspecified siteRift Valley feverPlague
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05172037
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05172037 through Pure Global AI's free database. This Phase 3 trial is sponsored by Genova Inc. and is currently Recruiting. The study focuses on Covid19. Target enrollment is 222 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.